BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1669 related articles for article (PubMed ID: 9537249)

  • 1. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
    Grauslund M; Thougaard AV; Füchtbauer A; Hofland KF; Hjorth PH; Jensen PB; Sehested M; Füchtbauer EM; Jensen LH
    Mol Pharmacol; 2007 Oct; 72(4):1003-14. PubMed ID: 17622580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H; Gosky D; Berger NA; Chatterjee S
    Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
    Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
    Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
    Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
    Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
    Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
    Webb CD; Latham MD; Lock RB; Sullivan DM
    Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.